Bretylium

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C11H17BrN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RZR75EQ2KJ, chemically known as benzenemethanaminium, 2-bromo-n-ethyl-n,n-dimethyl-, salt with 4-methylbenzenesulfonic acid (1:1) but generally known as bretylium, which bears US NIH Compound Identifier 2431. Bretylium most often comes in base, bromide, p-toluenesulfonate, and tosylate forms. European Medicines Agency schedules Bretylium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00867MIG. BRETYLIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, BRETYLIUM remains the US FDA Preferred Term for this commodity. Bretylium bears US NLM identifiers UMLS ID C0054040 and NCI Concept Code C77300. SMILES: CC[N+](C)(C)CC1=CC=CC=C1BR.